CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS TESTANT LE ROLE DE L’IFOSFAMIDE AU SEIN D’UNE ASSOCIATION DE CHIMIOTHERAPIE


Précédent Retour au menu principal  Suivant


référence

chimiothérapie

n

(stIV)

% RO

p

SM

p

Paccagnella,

1990

I. CDDP (100 mg/m2) + VP16

39

(25)

26

NS

6 m.

NS

II. CDDP(80 mg/m2) + VP16 + Ifo (5g/m2)

39

(26)

26

7 m.

Rosell,

1990

I. CDDP (120 mg/m2)+VDS+MMC

53

(29)

26


NS

32 s..

NS

II. CDDP(100 mg/m2)+VDS+Ifo (3g/m2)

50

(29)

20

30 s

Kosmidis,

1994

I. CDDP (120 mg/m2)+VBL

61

(23)

9

0,02

8 m

NS

II. Idem + Ifo(3g/m2)

75

(31)

31

8,8 m

Baron,

1994

I. CDDP (120 mg/m2)+VDS +MMC

93

(40)

28

NS

8,5 m

NS

II. CDDP (90 mg/m2)+MMC+ Ifo(5g/m2)

94

(38)

30

9,0 m

Erkisi,

1995

I. CDDP (100 mg/m2) + VP16

35

 

40


0,02

?


0,0008

II. Idem + Ifo

39

 

52

?

Sculier,

1998

I. CDDP(60mg/m²) + CBDCA (200mg/m²)

248

(235)

16

<0,001

27s

NS

II. Idem + Ifo (4,5 g/m²)

257

(247)

31

27s

Souquet,

2002

I. CDDP (80 mg/m²) + VNR

133

 

35

NS

10 m

NS

II. CDDP (75 mg/m²) + VNR + Ifo

126

 

36

8,2 m

Kodani,

2002

I. CDDP (100 mg/m²) + VDS

65

(34)

45

NS

37 s

0,13

II. Idem + Ifo

67

(37)

49

50 s



Références

(1) Paccagnella A, Favaretto A, Brandes A, Ghiotto C, Fornasiero A, Volpi A et al. Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer 1990; 65(12):2631-2634.

(2) Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C et al. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 1990; 65(8):1692-1699.

(3) Kosmidis P, Mylonakis N, Skarlos DV, Samantas E, Beer M, Theocharis D et al. A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials. Ann Oncol 1994; 5(2):159-162.

(4) Gonzalez BM, Feliu J, Espinosa E, Garcia GC, Blanco E, Garrido P et al. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group [see comments]. Ann Oncol 1994; 5(4):323-327.

(5) Erkisi M, Doran F, Burgut R, Kocabas A. A randomised trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer. Lung Cancer 1995; 12(3):237-246.

(6) Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V et al. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1998; 16(4):1388-1396.

(7) Souquet PJ, Tan EH, Rodrigues PJ, Van Klaveren R, Price A, Gatzemeier U et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002; 13(12):1853-1861.

(8) Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y et al. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 2002; 36(3):313-319.



Retour au début de la page